These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9435165)

  • 21. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
    Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
    J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
    Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
    Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Aug; 485():1-233. PubMed ID: 12571678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
    Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
    Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid.
    Rao GS; Ramesh S; Ahmad AH; Tripathi HC; Sharma LD; Malik JK
    Vet J; 2002 Jan; 163(1):85-93. PubMed ID: 11749141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoration of the uricosuric effect of probenecid after triglycylvasopressine administration in a gouty patient.
    Decaux G; Soupart A; Musch W; Hannotier P; Prospert F
    Clin Nephrol; 1998 Oct; 50(4):262-5. PubMed ID: 9799074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
    Panetta JC; Schaiquevich P; Santana VM; Stewart CF
    Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible involvement of organic anion and cation transporters in renal excretion of xanthine derivatives, 3-methylxanthine and enprofylline.
    Nadai M; Kato M; Yoshizumi H; Kimura M; Kurono S; Abe F; Saito H; Hasegawa T
    Life Sci; 2007 Sep; 81(15):1175-82. PubMed ID: 17897683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
    Beringer PM; Kriengkauykiat J; Zhang X; Hidayat L; Liu S; Louie S; Synold T; Burckart GJ; Rao PA; Shapiro B; Gill M
    Pharmacotherapy; 2008 Jul; 28(7):883-94. PubMed ID: 18576903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
    Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
    Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy.
    Carcaboso AM; Bramuglia GF; Chantada GL; Fandiño AC; Chiappetta DA; de Davila MT; Rubio MC; Abramson DH
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3761-7. PubMed ID: 17652749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
    Tahara H; Kusuhara H; Chida M; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1187-94. PubMed ID: 16291876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicology and Carcinogenesis Studies of Ochratoxin A (CAS No. 303-47-9) in F344/N Rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1989 May; 358():1-142. PubMed ID: 12695783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
    Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
    Santana VM; Zamboni WC; Kirstein MN; Tan M; Liu T; Gajjar A; Houghton PJ; Stewart CF
    Clin Cancer Res; 2003 Feb; 9(2):633-40. PubMed ID: 12576429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
    Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
    Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.